Retinoic acid (RA) exhibits chemotherapeutic and chemopreventive activities in a number of cancers, including breast cancer. RA therapy is however confounded by a marked toxicity of this agent at pharmacological doses and by development of RA-resistance in tumors. The biological activities of RA are mediated by the nuclear hormone receptors retinoic acid- and retinoid X- receptors (RARs and RXRs). In addition, RA binds in cells to two intracellular proteins, cellular RA binding proteins I and II (CRABP-I and CRABP-II). We previously found that CRABP-II (but not CRABP-I) facilitates the delivery of RA to the receptor that is activated by it, namely RAR. We found further that this activity of CRABP-II enhances the transcriptional activity of RAR, suggesting that the presence of the binding protein could sensitize cells to the biological activities of RA. Our recent data indeed indicate that CRABP-II expression enhances the responsiveness of cultured mammary carcinoma cells to RA-induced growth inhibition, and suppresses tumor development in two mouse models of breast cancer. Hence, CRABP-II may comprise a novel target for therapy and prevention of some cancers. To better understand the mechanisms underlying the activities of RA and CRABP-II in mammary carcinomas, this application has the following specific aims: (1) To identify target genes that are regulated by RA and CRABP-II in MCF-7 mammary carcinoma cells. Affymetrix expression arrays will be utilized to compare gene expression profiles of MCF-7 cells that express different levels of CRABP-II, in the absence of or upon treatment with RA. (2) To study the effects of CRABP-II and RA on tumor growth in transgenic breast cancer mouse models. The mouse model MMTV-neu/Erb-B2, in which breast tumors arise spontaneously and progress under immune surveillance, will be used. Two mouse models will be generated: MMTV-neu mice with disrupted expression of CRABP-II, and MMTV-neu mice that over-express CRABP-II in mammary tissue. Characterization of tumors that develop in mice expressing different levels of CRABP-II will allow us to assess the ability of the protein to inhibit tumorigenesis and to sensitize breast tumors to RA-induced growth inhibition in vivo. In addition, Affymetrix arrays will be used to analyze genes that are involved in the effects of CRABP-II expression and RA administration on tumor growth in MMTV-neu mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA107013-02
Application #
7018489
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Jhappan, Chamelli
Project Start
2005-02-16
Project End
2006-12-31
Budget Start
2006-02-01
Budget End
2006-12-31
Support Year
2
Fiscal Year
2006
Total Cost
$343,832
Indirect Cost
Name
Cornell University
Department
Nutrition
Type
Other Domestic Higher Education
DUNS #
872612445
City
Ithaca
State
NY
Country
United States
Zip Code
14850
Berry, Daniel C; Croniger, Colleen M; Ghyselinck, Norbert B et al. (2012) Transthyretin blocks retinol uptake and cell signaling by the holo-retinol-binding protein receptor STRA6. Mol Cell Biol 32:3851-9
Berry, Daniel C; O'Byrne, Sheila M; Vreeland, Amanda C et al. (2012) Cross talk between signaling and vitamin A transport by the retinol-binding protein receptor STRA6. Mol Cell Biol 32:3164-75
Berry, Daniel C; Jin, Hui; Majumdar, Avijit et al. (2011) Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. Proc Natl Acad Sci U S A 108:4340-5
Yasmin, Rubina; Kannan-Thulasiraman, Padmamalini; Kagechika, Hiroyuki et al. (2010) Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor's oligomeric switch. J Mol Biol 397:1121-31
Liu, Keyi; Cheng, Le; Flesken-Nikitin, Andrea et al. (2010) Conditional knockout of fibronectin abrogates mouse mammary gland lobuloalveolar differentiation. Dev Biol 346:11-24
Schug, Thaddeus T; Berry, Daniel C; Toshkov, Illia A et al. (2008) Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A 105:7546-51
Noy, Noa (2007) Ligand specificity of nuclear hormone receptors: sifting through promiscuity. Biochemistry 46:13461-7
Donato, Leslie J; Suh, Jean H; Noy, Noa (2007) Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res 67:609-15
Donato, Leslie J; Noy, Noa (2006) A fluorescence-based method for analyzing retinoic acid in biological samples. Anal Biochem 357:249-56
Donato, Leslie J; Noy, Noa (2005) Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res 65:8193-9